{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:44:09Z","timestamp":1777416249168,"version":"3.51.4"},"reference-count":47,"publisher":"e-Century Publishing Corporation","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Exp Pathol"],"DOI":"10.62347\/dwiw6941","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T07:28:22Z","timestamp":1753946902000},"page":"386-404","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of EGFR-TKI for EGFR-mutated NSCLC: systematic review and network meta-analysis"],"prefix":"10.62347","volume":"18","author":[{"given":"Haifeng","family":"Zan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Siegel RL, Giaquinto AN and Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024; 74: 12-49.","DOI":"10.3322\/caac.21820"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF and Heist RS. Lung cancer. Lancet 2021; 398: 535-554.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.","journal-title":"Int J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB and Morris D. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 Suppl: 277s-289s.","DOI":"10.1378\/chest.07-1381"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Shepherd FA, Bunn PA and Paz-Ares L. Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book 2013; 339-346.","DOI":"10.14694\/EdBook_AM.2013.33.339"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"BC","year":"2024","unstructured":"Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D’Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE and Hayashi H. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med 2024; 391: 1486-1498.","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-021-01561-7","article-title":"Amivantamab: first approval","volume":"81","author":"Syed","year":"2021","unstructured":"Syed YY. Amivantamab: first approval. Drugs 2021; 81: 1349-1353.","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM and Hang L. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2024; 22: 249-274.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"HA","year":"2023","unstructured":"Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D and Jänne PA. HERTHENA-Lung01, a Phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol 2023; 41: 5363-5375.","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2217\/fon-2023-0602","article-title":"HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI","volume":"20","author":"Mok","year":"2024","unstructured":"Mok T, Jänne PA, Nishio M, Novello S, Reck M, Steuer C, Wu YL, Fougeray R, Fan PD, Meng J, Sternberg DW, Esker S and Yu HA. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. Future Oncol 2024; 20: 969-980.","journal-title":"Future Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"MJ","year":"2025","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, Vicente Baz D, Sugawara S, Cobo M, Pérol M, Mascaux C, Poddubskaya E, Kitazono S, Hayashi H, Hong MH, Felip E, Hall R, Juan-Vidal O, Brungs D, Lu S, Garassino M, Chargualaf M, Zhang Y, Howarth P, Uema D, Lisberg A and Sands J; TROPION-Lung01 Trial Investigators. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025; 43: 260-272.","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mco2.105","article-title":"Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy","volume":"2","author":"Cheng","year":"2021","unstructured":"Cheng Y, Zhang T and Xu Q. Therapeutic advances in non-small cell lung cancer: focus on clinical development of targeted therapy and immunotherapy. MedComm (2020) 2021; 2: 692-729.","journal-title":"MedComm (2020)"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Liu GH, Chen T, Zhang X, Ma XL and Shi HS. Small molecule inhibitors targeting the cancers. MedComm (2020) 2022; 3: e181.","DOI":"10.1002\/mco2.181"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S and Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K and Fukuoka M; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.","journal-title":"Lancet Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","unstructured":"Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V and Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016; 17: 577-589.","journal-title":"Lancet Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"YL","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R and Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18: 1454-1466.","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P and Green JA. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev 2016; CD010383.","DOI":"10.1002\/14651858.CD010383.pub2"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.20892\/j.issn.2095-3941.2024.0592","article-title":"Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC","volume":"22","author":"Chen","year":"2025","unstructured":"Chen S, Wang Z and Sun B. Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC. Cancer Biol Med 2025; 22: 191-196.","journal-title":"Cancer Biol Med"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Wood DE, Kazerooni EA, Aberle DR, Argento C, Baines J, Boer B, Brown LM, Donington J, Eapen GA and Ferguson JS. NCCN guidelines® insights: lung cancer screening, version 1.2025. J Natl Compr Canc Netw 2025; 23: e250002.","DOI":"10.6004\/jnccn.2025.0002"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","article-title":"Safety and tolerability of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors in oncology","volume":"42","author":"Shah","year":"2019","unstructured":"Shah RR and Shah DR. Safety and tolerability of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf 2019; 42: 181-198.","journal-title":"Drug Saf"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3747\/co.22.2430","article-title":"Management of egfr tki-induced dermatologic adverse events","volume":"22","author":"Melosky","year":"2015","unstructured":"Melosky B, Leighl NB, Rothenstein J, Sangha R, Stewart D and Papp K. Management of egfr tki-induced dermatologic adverse events. Curr Oncol 2015; 22: 123-132.","journal-title":"Curr Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jtho.2016.11.2236","article-title":"Risk of treatment-related toxicities from egfr tyrosine kinase inhibitors: a meta-analysis of clinical trials of Gefitinib, Erlotinib, and Afatinib in advanced EGFR-mutated non-small cell lung cancer","volume":"12","author":"Ding","year":"2017","unstructured":"Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC and Lee CK. Risk of treatment-related toxicities from egfr tyrosine kinase inhibitors: a meta-analysis of clinical trials of Gefitinib, Erlotinib, and Afatinib in advanced EGFR-mutated non-small cell lung cancer. J Thorac Oncol 2017; 12: 633-643.","journal-title":"J Thorac Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.lungcan.2015.01.026","article-title":"Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer","volume":"88","author":"Takeda","year":"2015","unstructured":"Takeda M, Okamoto I and Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer 2015; 88: 74-79.","journal-title":"Lung Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2","volume":"14","author":"Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M and Barrett A. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14: 429-437.","journal-title":"Value Health"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1","volume":"14","author":"Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L and Cappelleri JC. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health 2011; 14: 417-428.","journal-title":"Value Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","volume":"16","author":"Cheng","year":"2021","unstructured":"Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, Liu C, Walding A, Saggese M, Huang X, Fan M, Wang J and Ramalingam SS. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study. Target Oncol 2021; 16: 165-176.","journal-title":"Target Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2021.02.025","article-title":"Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (ARCHER 1050)","volume":"154","author":"Cheng","year":"2021","unstructured":"Cheng Y, Mok TS, Zhou X, Lu S, Zhou Q, Zhou J, Du Y, Yu P, Liu X, Hu C, Lu Y, Zhang Y, Lee KH, Nakagawa K, Linke R, Wong CH, Tang Y, Zhu F, Wilner KD and Wu YL. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer 2021; 154: 176-185.","journal-title":"Lung Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12890-018-0734-1","article-title":"Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study","volume":"18","author":"Jiang","year":"2018","unstructured":"Jiang Y, Zhang J, Huang J, Xu B, Li N, Cao L and Zhao M. Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study. BMC Pulm Med 2018; 18: 171.","journal-title":"BMC Pulm Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or Metastaticnon-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","unstructured":"Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA and Wu Q. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or Metastaticnon-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations. J Clin Oncol 2022; 40: 3162-3171.","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares L","year":"2017","unstructured":"Paz-Ares L, Tan EH, O’Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A and Park K. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 2017; 28: 270-277.","journal-title":"Ann Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.lanwpc.2024.101122","article-title":"Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer","volume":"48","author":"Shi","year":"2024","unstructured":"Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Hu J, Liu F, Jiang Y and Ge N. Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer. Lancet Reg Health West Pac 2024; 48: 101122.","journal-title":"Lancet Reg Health West Pac"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","unstructured":"Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W and Sun Y. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013; 14: 953-961.","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","article-title":"Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)","volume":"29","author":"Fukuoka","year":"2011","unstructured":"Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC and Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-2874.","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M and Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","unstructured":"Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL and Sun Y. First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol 2017; 28: 2443-2450.","journal-title":"Ann Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","article-title":"Efficacy of Aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial","volume":"17","author":"Lu","year":"2022","unstructured":"Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, Chang GC, Lu Y, Pan H, Chiu CH, Wang Z, Feng J, Zhou J, Xu X, Guo R, Chen J, Yang H, Chen Y, Yu Z, Shiah HS, Wang CC, Yang N, Fang J, Wang P, Wang K, Hu Y, He J, Wang Z, Shi J, Chen S, Wu Q, Sun C, Li C, Wei H, Cheng Y, Su WC, Hsia TC, Cui J, Sun Y, Ou SI, Zhu VW and Chih-Hsin Yang J. Efficacy of Aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial. J Thorac Oncol 2022; 17: 411-422.","journal-title":"J Thorac Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","unstructured":"Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, Zhu S, Zhang X, Li Y, Liu J, Cao L, Cheng Y, Zhao H, Zhang S, Zang A, Cui J, Feng J, Yang N, Liu F, Jiang Y and Gu C; FURLONG investigators. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med 2022; 10: 1019-1028.","journal-title":"Lancet Respir Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","unstructured":"Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S and Wrigley GL. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014; 57: 8249-8267.","journal-title":"J Med Chem"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.critrevonc.2017.07.003","article-title":"Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going","volume":"117","author":"Russo","year":"2017","unstructured":"Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghì M, Rolfo C and Adamo V. Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going. Crit Rev Oncol Hematol 2017; 117: 38-47.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"YL","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y and Herbst RS; ADAURA Investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020; 383: 1711-1723.","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","article-title":"Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial","volume":"6","author":"Yue","year":"2018","unstructured":"Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H and Wang C. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med 2018; 6: 863-873.","journal-title":"Lancet Respir Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1200\/JCO.20.01820","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 Phase III trial","volume":"39","author":"Zhong","year":"2021","unstructured":"Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yang JJ, Yan HH, Yang XN, Liu SY, Zhou Q and Wu YL. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 Phase III trial. J Clin Oncol 2021; 39: 713-722.","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/jdv.20391","article-title":"Management of human epidermal growth factor receptor inhibitors-related acneiform rash: a position paper based on the first Europe\/USA Delphi consensus process","volume":"39","author":"Apalla","year":"2025","unstructured":"Apalla Z, Freites-Martinez A, Grafanaki K, Ortiz-Brugues A, Nikolaou V, Fattore D, Sollena P, Deverapalli S, Babakoohi S, Galimont A, Kluger N, Beylot-Barry M, Larocca C, Iriarte C, Smith J, Tattersall I, Dodiuk-Gad R, Sauder M, Carrera C, Kwong B, Whitley M, Leboeuf N, Romano P, Starace M, Mateeva V, Riganti J, Hirner J, Patel AB, Reyes-Habito CM, Kraehenbuehl L, Kheterpal M, Fida M, Hassel J, Lacouture M and Sibaud V. Management of human epidermal growth factor receptor inhibitors-related acneiform rash: a position paper based on the first Europe\/USA Delphi consensus process. J Eur Acad Dermatol Venereol 2025; 39: 730-741.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/ajco.13740","article-title":"Prevention and management of acneiform rash associated with EGFR inhibitor therapy: a systematic review and meta-analysis","volume":"18","author":"Gorji","year":"2022","unstructured":"Gorji M, Joseph J, Pavlakis N and Smith SD. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: a systematic review and meta-analysis. Asia Pac J Clin Oncol 2022; 18: 526-539.","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s00520-020-05765-7","article-title":"Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512)","volume":"29","author":"Nishino","year":"2021","unstructured":"Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, Nakai Y, Takahashi T, Shibata T, Hamaguchi T, Kikuchi K, Yamazaki N, Fukuda H, Nozawa K and Kiyohara Y. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). Support Care Cancer 2021; 29: 2327-2334.","journal-title":"Support Care Cancer"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/ajco.12687","article-title":"Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities","volume":"14","author":"DC","year":"2018","unstructured":"Aw DC, Tan EH, Chin TM, Lim HL, Lee HY and Soo RA. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia Pac J Clin Oncol 2018; 14: 23-31.","journal-title":"Asia Pac J Clin Oncol"}],"container-title":["International Journal of Clinical and Experimental Pathology"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ijcep\/18\/7\/ijcep0165658.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:56:26Z","timestamp":1766022986000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ijcep\/18\/7\/ijcep0165658.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/dwiw6941","relation":{},"ISSN":["1936-2625"],"issn-type":[{"value":"1936-2625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}